{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:14:04Z","timestamp":1791983644987,"version":"4.4.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000066","name":"U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30ES013508"],"award-info":[{"award-number":["P30ES013508"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30ES013508"],"award-info":[{"award-number":["P30ES013508"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-024-06930-y","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T12:01:54Z","timestamp":1727784114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["HMGB2-induced calreticulin translocation required for immunogenic cell death and ferroptosis of cancer cells are controlled by the nuclear exporter XPO1"],"prefix":"10.1038","volume":"7","author":[{"given":"Jingqi","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"Mesaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0366-8658","authenticated-orcid":false,"given":"Ian A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"6930_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.pharma.2011.10.001","volume":"69","author":"C Monneret","year":"2011","unstructured":"Monneret, C. Platinum anticancer drugs. From serendipity to rational design. Ann. Pharm. Fr. 69, 286\u2013295 (2011).","journal-title":"Ann. Pharm. Fr."},{"key":"6930_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482\u2013491 (2010).","journal-title":"Oncogene"},{"key":"6930_CR3","doi-asserted-by":"publisher","unstructured":"Gillespie, K. P., Pirnie, R., Mesaros, C. & Blair, I. A. Cisplatin dependent secretion of immunomodulatory high mobility group box 1 (HMGB1) protein from lung cancer cells. Biomolecules https:\/\/doi.org\/10.3390\/biom13091335 (2023).","DOI":"10.3390\/biom13091335"},{"key":"6930_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 11, 1013 (2020).","journal-title":"Cell Death Dis."},{"key":"6930_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691\u20131701 (2005).","journal-title":"J. Exp. Med."},{"key":"6930_CR6","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1021\/acs.analchem.8b01175","volume":"90","author":"L Weng","year":"2018","unstructured":"Weng, L., Guo, L., Vachani, A., Mesaros, C. & Blair, I. A. Quantification of serum high mobility group box 1 by liquid chromatography\/high-resolution mass spectrometry: implications for its role in immunity, inflammation, and cancer. Anal. Chem. 90, 7552\u20137560 (2018).","journal-title":"Anal. Chem."},{"key":"6930_CR7","doi-asserted-by":"publisher","unstructured":"Starkova, T., Polyanichko, A., Tomilin, A. N. & Chikhirzhina, E. Structure and functions of HMGB2 protein. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24098334 (2023).","DOI":"10.3390\/ijms24098334"},{"key":"6930_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nri1594","volume":"5","author":"MT Lotze","year":"2005","unstructured":"Lotze, M. T. & Tracey, K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331\u2013342 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"6930_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920970850","volume":"12","author":"L Niu","year":"2020","unstructured":"Niu, L. et al. Biological functions and theranostic potential of HMGB family members in human cancers. Ther. Adv. Med. Oncol. 12, 1758835920970850 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"6930_CR10","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.2174\/1570159X20666220114153308","volume":"20","author":"FZ Ikram","year":"2022","unstructured":"Ikram, F. Z., Arulsamy, A., Retinasamy, T. & Shaikh, M. F. The role of high mobility group box 1 (HMGB1) in neurodegeneration: a systematic review. Curr. Neuropharmacol. 20, 2221\u20132245 (2022).","journal-title":"Curr. Neuropharmacol."},{"key":"6930_CR11","doi-asserted-by":"publisher","unstructured":"Paudel, Y. N. et al. Impact of HMGB1, RAGE, and TLR4 in Alzheimer\u2019s Disease (AD): from risk factors to therapeutic targeting. Cells https:\/\/doi.org\/10.3390\/cells9020383 (2020).","DOI":"10.3390\/cells9020383"},{"key":"6930_CR12","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1089\/ars.2019.7818","volume":"31","author":"M Wang","year":"2019","unstructured":"Wang, M. et al. The role of HMGB1, a nuclear damage-associated molecular pattern molecule, in the pathogenesis of lung diseases. Antioxid. Redox Signal 31, 954\u2013993 (2019).","journal-title":"Antioxid. Redox Signal"},{"key":"6930_CR13","doi-asserted-by":"publisher","first-page":"50417","DOI":"10.18632\/oncotarget.10413","volume":"7","author":"T Wu","year":"2016","unstructured":"Wu, T. et al. HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget 7, 50417\u201350427 (2016).","journal-title":"Oncotarget"},{"key":"6930_CR14","doi-asserted-by":"publisher","first-page":"e34318","DOI":"10.1371\/journal.pone.0034318","volume":"7","author":"H Lee","year":"2012","unstructured":"Lee, H. et al. Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS ONE 7, e34318 (2012).","journal-title":"PLoS ONE"},{"key":"6930_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JP9.0000000000000002","volume":"1","author":"R Kang","year":"2018","unstructured":"Kang, R. & Tang, D. The dual role of HMGB1 in pancreatic cancer. J. Pancreatol. 1, 19\u201324 (2018).","journal-title":"J. Pancreatol."},{"key":"6930_CR16","doi-asserted-by":"publisher","unstructured":"Plemmenos, G., Tzimogianni, V., Fili, C. & Piperi, C. Contributing role of high mobility group box 1 signaling in oral cancer development and therapy. Life https:\/\/doi.org\/10.3390\/life13071577 (2023).","DOI":"10.3390\/life13071577"},{"key":"6930_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5845061","volume":"2016","author":"A Barreiro-Alonso","year":"2016","unstructured":"Barreiro-Alonso, A. et al. High mobility group B proteins, their partners, and other redox sensors in ovarian and prostate cancer. Oxid. Med. Cell. Longev. 2016, 5845061 (2016).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"6930_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4149\/neo_2014_070","volume":"61","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Serum high mobility group box protein 1 as aclinical marker for ovarian cancer. Neoplasma 61, 579\u2013584 (2014).","journal-title":"Neoplasma"},{"key":"6930_CR19","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1002\/jcb.26837","volume":"119","author":"XJ Wu","year":"2018","unstructured":"Wu, X. J., Chen, Y. Y., Gong, C. C. & Pei, D. S. The role of high-mobility group protein box 1 in lung cancer. J. Cell Biochem. 119, 6354\u20136365 (2018).","journal-title":"J. Cell Biochem."},{"key":"6930_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/path.1031","volume":"196","author":"H Kuniyasu","year":"2002","unstructured":"Kuniyasu, H. et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J. Pathol. 196, 163\u2013170 (2002).","journal-title":"J. Pathol."},{"key":"6930_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1097-0215(19970220)74:1<1::AID-IJC1>3.0.CO;2-6","volume":"74","author":"YY Xiang","year":"1997","unstructured":"Xiang, Y. Y. et al. Expression of high-mobility group-1 mRNA in human gastrointestinal adenocarcinoma and corresponding non-cancerous mucosa. Int. J. Cancer 74, 1\u20136 (1997).","journal-title":"Int. J. Cancer"},{"key":"6930_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000086627","volume":"69","author":"N Oue","year":"2005","unstructured":"Oue, N. et al. Genes involved in invasion and metastasis of gastric cancer identified by array-based hybridization and serial analysis of gene expression. Oncology 69, 17\u201322 (2005).","journal-title":"Oncology"},{"key":"6930_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2011.08.028","volume":"313","author":"H Liang","year":"2011","unstructured":"Liang, H., Zhong, Y., Zhou, S. & Peng, L. Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo. Cancer Lett. 313, 91\u201398 (2011).","journal-title":"Cancer Lett."},{"key":"6930_CR24","doi-asserted-by":"publisher","unstructured":"Chen, J. et al. HMGB1 promotes the development of castration\u2011resistant prostate cancer by regulating androgen receptor activation. Oncol. Rep. https:\/\/doi.org\/10.3892\/or.2022.8412 (2022).","DOI":"10.3892\/or.2022.8412"},{"key":"6930_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-165","volume":"13","author":"B Pan","year":"2014","unstructured":"Pan, B. et al. HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma. Mol. Cancer 13, 165 (2014).","journal-title":"Mol. Cancer"},{"key":"6930_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/08916930902831845","volume":"42","author":"T Pusterla","year":"2009","unstructured":"Pusterla, T., de Marchis, F., Palumbo, R. & Bianchi, M. E. High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity 42, 308\u2013310 (2009).","journal-title":"Autoimmunity"},{"key":"6930_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41352-0","volume":"14","author":"EN Neubert","year":"2023","unstructured":"Neubert, E. N. et al. HMGB2 regulates the differentiation and stemness of exhausted CD8(+) T cells during chronic viral infection and cancer. Nat. Commun. 14, 5631 (2023).","journal-title":"Nat. Commun."},{"key":"6930_CR28","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1242\/dev.128.8.1265","volume":"128","author":"L Ronfani","year":"2001","unstructured":"Ronfani, L. et al. Reduced fertility and spermatogenesis defects in mice lacking chromosomal protein Hmgb2. Development 128, 1265\u20131273 (2001).","journal-title":"Development"},{"key":"6930_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-5956-11-18","volume":"11","author":"AB Abraham","year":"2013","unstructured":"Abraham, A. B. et al. Members of the high mobility group B protein family are dynamically expressed in embryonic neural stem cells. Proteome Sci. 11, 18 (2013).","journal-title":"Proteome Sci."},{"key":"6930_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000356667","volume":"33","author":"T Benavides Damm","year":"2014","unstructured":"Benavides Damm, T. & Egli, M. Calcium\u2019s role in mechanotransduction during muscle development. Cell. Physiol. Biochem. 33, 249\u2013272 (2014).","journal-title":"Cell. Physiol. Biochem."},{"key":"6930_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jim.2018.02.006","volume":"456","author":"JE Davies","year":"2018","unstructured":"Davies, J. E., Apta, B. H. R. & Harper, M. T. Cross-reactivity of anti-HMGB1 antibodies for HMGB2. J. Immunol. Methods 456, 72\u201376 (2018).","journal-title":"J. Immunol. Methods"},{"key":"6930_CR32","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1021\/acs.chemrestox.2c00161","volume":"35","author":"R Pirnie","year":"2022","unstructured":"Pirnie, R., Gillespie, K. P., Weng, L., Mesaros, C. & Blair, I. A. Characterization and quantification of oxidized high mobility group box 1 proteoforms secreted from hepatocytes by toxic levels of acetaminophen. Chem. Res. Toxicol. 35, 1893\u20131902 (2022).","journal-title":"Chem. Res. Toxicol."},{"key":"6930_CR33","doi-asserted-by":"publisher","unstructured":"Gargantilla, M. et al. Inhibition of XPO-1 mediated nuclear export through the michael-acceptor character of chalcones. Pharmaceuticals https:\/\/doi.org\/10.3390\/ph14111131 (2021).","DOI":"10.3390\/ph14111131"},{"key":"6930_CR34","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00432-022-04247-z","volume":"149","author":"JR Landes","year":"2023","unstructured":"Landes, J. R. et al. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review. J. Cancer Res. Clin. Oncol. 149, 2139\u20132155 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"6930_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep16077","volume":"5","author":"AS Azmi","year":"2015","unstructured":"Azmi, A. S. et al. Targeting the nuclear export protein XPO1\/CRM1 reverses epithelial to mesenchymal transition. Sci. Rep. 5, 16077 (2015).","journal-title":"Sci. Rep."},{"key":"6930_CR36","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-16-2632","volume":"23","author":"JS Nair","year":"2017","unstructured":"Nair, J. S., Musi, E. & Schwartz, G. K. Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IkappaB and downregulation of survivin. Clin. Cancer Res. 23, 4301\u20134311 (2017).","journal-title":"Clin. Cancer Res."},{"key":"6930_CR37","doi-asserted-by":"publisher","first-page":"82144","DOI":"10.18632\/oncotarget.19285","volume":"8","author":"AS Azmi","year":"2017","unstructured":"Azmi, A. S. et al. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget 8, 82144\u201382155 (2017).","journal-title":"Oncotarget"},{"key":"6930_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/sci.2019.02.03","volume":"6","author":"AY Wang","year":"2019","unstructured":"Wang, A. Y. & Liu, H. The past, present, and future of CRM1\/XPO1 inhibitors. Stem Cell Investig. 6, 6 (2019).","journal-title":"Stem Cell Investig."},{"key":"6930_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"NG Azizian","year":"2020","unstructured":"Azizian, N. G. & Li, Y. XPO1-dependent nuclear export as a target for cancer therapy. J. Hematol. Oncol. 13, 61 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"6930_CR40","first-page":"S178","volume":"87","author":"E Kim","year":"2022","unstructured":"Kim, E., Mordovkina, D. A. & Sorokin, A. Targeting XPO1-dependent nuclear export in cancer. Biochemistry 87, S178\u2013S191 (2022).","journal-title":"Biochemistry"},{"key":"6930_CR41","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487\u2013500 (2022).","journal-title":"Nat. Immunol."},{"key":"6930_CR42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2219591","volume":"12","author":"J Sprooten","year":"2023","unstructured":"Sprooten, J. et al. Trial watch: chemotherapy-induced immunogenic cell death in oncology. Oncoimmunology 12, 2219591 (2023).","journal-title":"Oncoimmunology"},{"key":"6930_CR43","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/35073038","volume":"2","author":"C Robinson","year":"2001","unstructured":"Robinson, C. & Bolhuis, A. Protein targeting by the twin-arginine translocation pathway. Nat. Rev. Mol. Cell Biol. 2, 350\u2013356 (2001).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"6930_CR44","doi-asserted-by":"publisher","unstructured":"Wang, Y., Fan, S., Zhong, W., Zhou, X. & Li, S. Development and properties of valine-alanine based antibody-drug conjugates with monomethyl auristatin E as the potent payload. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms18091860 (2017).","DOI":"10.3390\/ijms18091860"},{"key":"6930_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117146","volume":"241","author":"WJ Liang","year":"2020","unstructured":"Liang, W. J., Yang, H. W., Liu, H. N., Qian, W. & Chen, X. L. HMGB1 upregulates NF-kB by inhibiting IKB-alpha and associates with diabetic retinopathy. Life Sci. 241, 117146 (2020).","journal-title":"Life Sci."},{"key":"6930_CR46","doi-asserted-by":"publisher","first-page":"2157355","DOI":"10.1155\/2023\/2157355","volume":"2023","author":"H Wu","year":"2023","unstructured":"Wu, H. et al. HMGB2 deficiency mitigates abdominal aortic aneurysm by suppressing Ang-II-caused ferroptosis and inflammation via NF-kappabeta pathway. Mediators Inflamm. 2023, 2157355 (2023).","journal-title":"Mediators Inflamm."},{"key":"6930_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122007","volume":"330","author":"E Casper","year":"2023","unstructured":"Casper, E. The crosstalk between Nrf2 and NF-kappaB pathways in coronary artery disease: can it be regulated by SIRT6? Life Sci. 330, 122007 (2023).","journal-title":"Life Sci."},{"key":"6930_CR48","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00204-023-03660-8","volume":"98","author":"Y Xiang","year":"2024","unstructured":"Xiang, Y., Song, X. & Long, D. Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases. Arch. Toxicol. 98, 579\u2013615 (2024).","journal-title":"Arch. Toxicol."},{"key":"6930_CR49","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3389\/fphar.2020.01061","volume":"11","author":"X Lin","year":"2020","unstructured":"Lin, X., Ping, J., Wen, Y. & Wu, Y. The mechanism of ferroptosis and applications in tumor treatment. Front. Pharmacol. 11, 1061 (2020).","journal-title":"Front. Pharmacol."},{"key":"6930_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2024.152135","volume":"126","author":"M Wang","year":"2024","unstructured":"Wang, M. et al. Protective effect of FXN overexpression on ferroptosis in L-Glu-induced SH-SY5Y cells. Acta Histochem. 126, 152135 (2024).","journal-title":"Acta Histochem."},{"key":"6930_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41490-x","volume":"13","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis. Sci. Rep. 13, 14359 (2023).","journal-title":"Sci. Rep."},{"key":"6930_CR52","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.tips.2023.08.012","volume":"44","author":"C Scarpellini","year":"2023","unstructured":"Scarpellini, C. et al. Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors. Trends Pharmacol. Sci. 44, 902\u2013916 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"6930_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2016.06.008","volume":"109","author":"M Oparka","year":"2016","unstructured":"Oparka, M. et al. Quantifying ROS levels using CM-H(2)DCFDA and HyPer. Methods 109, 3\u201311 (2016).","journal-title":"Methods"},{"key":"6930_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-0716-3433-2_6","volume":"2712","author":"Z Dai","year":"2023","unstructured":"Dai, Z., Zhang, W., Zhou, L. & Huang, J. Probing lipid peroxidation in ferroptosis: emphasizing the utilization of C11-BODIPY-based protocols. Methods Mol. Biol. 2712, 61\u201372 (2023).","journal-title":"Methods Mol. Biol."},{"key":"6930_CR55","doi-asserted-by":"publisher","first-page":"2915019","DOI":"10.1155\/2021\/2915019","volume":"2021","author":"S Li","year":"2021","unstructured":"Li, S. et al. RSL3 drives ferroptosis through NF-kappaB pathway activation and GPX4 depletion in glioblastoma. Oxid. Med. Cell. Longev. 2021, 2915019 (2021).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"6930_CR56","doi-asserted-by":"publisher","first-page":"13515","DOI":"10.18632\/aging.202774","volume":"13","author":"C Yang","year":"2021","unstructured":"Yang, C., Zhang, Y., Lin, S., Liu, Y. & Li, W. Suppressing the KIF20A\/NUAK1\/Nrf2\/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin. Aging 13, 13515\u201313534 (2021).","journal-title":"Aging"},{"key":"6930_CR57","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1080\/10717544.2022.2096711","volume":"29","author":"WA Al-Otaibi","year":"2022","unstructured":"Al-Otaibi, W. A. & AlMotwaa, S. M. Oxaliplatin-loaded nanoemulsion containing Teucrium polium L. essential oil induces apoptosis in colon cancer cell lines through ROS-mediated pathway. Drug Deliv. 29, 2190\u20132205 (2022).","journal-title":"Drug Deliv."},{"key":"6930_CR58","doi-asserted-by":"publisher","first-page":"102822","DOI":"10.1016\/j.redox.2023.102822","volume":"65","author":"Y He","year":"2023","unstructured":"He, Y. et al. Butyrate reverses ferroptosis resistance in colorectal cancer by inducing c-Fos-dependent xCT suppression. Redox Biol. 65, 102822 (2023).","journal-title":"Redox Biol."},{"key":"6930_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202304521","volume":"10","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. FOXA2 suppression by TRIM36 exerts anti-tumor role in colorectal cancer via inducing NRF2\/GPX4-regulated ferroptosis. Adv. Sci. 10, e2304521 (2023).","journal-title":"Adv. Sci."},{"key":"6930_CR60","first-page":"2093","volume":"26","author":"S William-Faltaos","year":"2006","unstructured":"William-Faltaos, S., Rouillard, D., Lechat, P. & Bastian, G. Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines. Anticancer Res. 26, 2093\u20132099 (2006).","journal-title":"Anticancer Res."},{"key":"6930_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","volume":"15","author":"A Tesniere","year":"2008","unstructured":"Tesniere, A. et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15, 3\u201312 (2008).","journal-title":"Cell Death Differ."},{"key":"6930_CR62","doi-asserted-by":"publisher","first-page":"C917","DOI":"10.1152\/ajpcell.00401.2005","volume":"290","author":"JS Park","year":"2006","unstructured":"Park, J. S. et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290, C917\u2013C924 (2006).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"6930_CR63","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/01.shk.0000225404.51320.82","volume":"26","author":"M Yu","year":"2006","unstructured":"Yu, M. et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26, 174\u2013179 (2006).","journal-title":"Shock"},{"key":"6930_CR64","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/ni1457","volume":"8","author":"J Tian","year":"2007","unstructured":"Tian, J. et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487\u2013496 (2007).","journal-title":"Nat. Immunol."},{"key":"6930_CR65","doi-asserted-by":"publisher","first-page":"25752","DOI":"10.1074\/jbc.270.43.25752","volume":"270","author":"O Hori","year":"1995","unstructured":"Hori, O. et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270, 25752\u201325761 (1995).","journal-title":"J. Biol. Chem."},{"key":"6930_CR66","doi-asserted-by":"publisher","unstructured":"Watanabe, H. & Son, M. The immune tolerance role of the HMGB1-RAGE Axis. Cells https:\/\/doi.org\/10.3390\/cells10030564 (2021).","DOI":"10.3390\/cells10030564"},{"key":"6930_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s10020-023-00717-3","volume":"29","author":"W Ren","year":"2023","unstructured":"Ren, W., Zhao, L., Sun, Y., Wang, X. & Shi, X. HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases. Mol. Med. 29, 117 (2023).","journal-title":"Mol. Med."},{"key":"6930_CR68","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","volume":"23","author":"D Tang","year":"2023","unstructured":"Tang, D., Kang, R., Zeh, H. J. & Lotze, M. T. The multifunctional protein HMGB1: 50 years of discovery. Nat. Rev. Immunol. 23, 824\u2013841 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"6930_CR69","doi-asserted-by":"publisher","first-page":"H422","DOI":"10.1152\/ajpheart.00249.2016","volume":"312","author":"ZH Liu","year":"2017","unstructured":"Liu, Z. H. et al. Association of serum HMGB2 level with MACE at 1 mo of myocardial infarction: aggravation of myocardial ischemic injury in rats by HMGB2 via ROS. Am. J. Physiol. Heart Circ. Physiol. 312, H422\u2013H436 (2017).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"6930_CR70","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","volume":"16","author":"L Zitvogel","year":"2010","unstructured":"Zitvogel, L. et al. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin. Cancer Res. 16, 3100\u20133104 (2010).","journal-title":"Clin. Cancer Res."},{"key":"6930_CR71","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/onc.2010.500","volume":"30","author":"I Martins","year":"2011","unstructured":"Martins, I. et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30, 1147\u20131158 (2011).","journal-title":"Oncogene"},{"key":"6930_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2023.102277","volume":"73","author":"S Sen","year":"2023","unstructured":"Sen, S., Karoscik, K., Maier, E. & Arambula, J. F. Immunogenic cell death-inducing metal complexes: from the benchtop to the clinic. Curr. Opin. Chem. Biol. 73, 102277 (2023).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"6930_CR73","volume":"29","author":"K Matsusaka","year":"2022","unstructured":"Matsusaka, K. et al. Distinct roles in phagocytosis of the early and late increases of cell surface calreticulin induced by oxaliplatin. Biochem. Biophys. Rep. 29, 101222 (2022).","journal-title":"Biochem. Biophys. Rep."},{"key":"6930_CR74","first-page":"215","volume":"497","author":"D O\u2019Dowd","year":"2023","unstructured":"O\u2019Dowd, D., Sutcliffe, D. F. & Griffith, D. M. Oxaliplatin and its derivatives \u2013 an overview. Coord. Chem. Rev. 497, 215\u2013439 (2023).","journal-title":"Coord. Chem. Rev."},{"key":"6930_CR75","doi-asserted-by":"publisher","first-page":"1152934","DOI":"10.3389\/fphar.2023.1152934","volume":"14","author":"J Zhai","year":"2023","unstructured":"Zhai, J. et al. Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: an update review. Front. Pharmacol. 14, 1152934 (2023).","journal-title":"Front. Pharmacol."},{"key":"6930_CR76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","volume":"54","author":"R Chen","year":"2022","unstructured":"Chen, R., Kang, R. & Tang, D. The mechanism of HMGB1 secretion and release. Exp. Mol. Med. 54, 91\u2013102 (2022).","journal-title":"Exp. Mol. Med."},{"key":"6930_CR77","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/mc.22312","volume":"55","author":"B Bian","year":"2016","unstructured":"Bian, B. et al. Cathepsin B promotes colorectal tumorigenesis, cell invasion, and metastasis. Mol. Carcinog. 55, 671\u2013687 (2016).","journal-title":"Mol. Carcinog."},{"key":"6930_CR78","doi-asserted-by":"crossref","unstructured":"Siwach, K. et al. 1,2,3-Triazole-based esters and carboxylic acids as nonclassical carbonic anhydrase inhibitors capable of cathepsin B inhibition. Arch. Pharm. 357, e2300372 (2023).","DOI":"10.1002\/ardp.202300372"},{"key":"6930_CR79","doi-asserted-by":"publisher","first-page":"7449","DOI":"10.1038\/sj.onc.1208047","volume":"23","author":"I Gourdier","year":"2004","unstructured":"Gourdier, I., Crabbe, L., Andreau, K., Pau, B. & Kroemer, G. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 23, 7449\u20137457 (2004).","journal-title":"Oncogene"},{"key":"6930_CR80","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41573-023-00749-8","volume":"22","author":"K Hadian","year":"2023","unstructured":"Hadian, K. & Stockwell, B. R. The therapeutic potential of targeting regulated non-apoptotic cell death. Nat. Rev. Drug Discov. 22, 723\u2013742 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"6930_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.637162","volume":"9","author":"X Chen","year":"2021","unstructured":"Chen, X., Comish, P. B., Tang, D. & Kang, R. Characteristics and biomarkers of ferroptosis. Front. Cell Dev. Biol. 9, 637162 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"6930_CR82","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell, B. R. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell 185, 2401\u20132421 (2022).","journal-title":"Cell"},{"key":"6930_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175093","volume":"928","author":"P Hu","year":"2022","unstructured":"Hu, P. et al. The mechanism of the imbalance between proliferation and ferroptosis in pulmonary artery smooth muscle cells based on the activation of SLC7A11. Eur. J. Pharmacol. 928, 175093 (2022).","journal-title":"Eur. J. Pharmacol."},{"key":"6930_CR84","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1124\/jpet.118.252759","volume":"369","author":"MG Cotticelli","year":"2019","unstructured":"Cotticelli, M. G. et al. Ferroptosis as a novel therapeutic target for Friedreich\u2019s Ataxia. J. Pharmacol. Exp. Ther. 369, 47\u201354 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"6930_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113252","volume":"42","author":"N Koutsodendris","year":"2023","unstructured":"Koutsodendris, N. et al. APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release. Cell Rep. 42, 113252 (2023).","journal-title":"Cell Rep."},{"key":"6930_CR86","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2093518","volume":"11","author":"P Liu","year":"2022","unstructured":"Liu, P. et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology 11, 2093518 (2022).","journal-title":"Oncoimmunology"},{"key":"6930_CR87","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2272352","volume":"12","author":"L Bezu","year":"2023","unstructured":"Bezu, L., Kepp, O. & Kroemer, G. Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors. Oncoimmunology 12, 2272352 (2023).","journal-title":"Oncoimmunology"},{"key":"6930_CR88","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/pro.3993","volume":"30","author":"AB Schroeder","year":"2021","unstructured":"Schroeder, A. B. et al. The ImageJ ecosystem: open-source software for image visualization, processing, and analysis. Protein Sci. 30, 234\u2013249 (2021).","journal-title":"Protein Sci."},{"key":"6930_CR89","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","volume":"26","author":"B MacLean","year":"2010","unstructured":"MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966\u2013968 (2010).","journal-title":"Bioinformatics"}],"updated-by":[{"DOI":"10.1038\/s42003-025-08894-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000}}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06930-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06930-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06930-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T07:01:52Z","timestamp":1759647712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06930-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6930"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-06930-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4009459\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-4009459\/v2","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s42003-025-08894-z","URL":"https:\/\/doi.org\/10.1038\/s42003-025-08894-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.A.B. has sponsored research agreements with Lexeo Therapeutics and Design Therapeutics. A provisional patent is pending for CT-HMGB2 and its analogs.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1234"}}